mAbxience Revenue and Competitors
Estimated Revenue & Valuation
- mAbxience's estimated annual revenue is currently $187.2M per year.
- mAbxience's estimated revenue per employee is $155,000
Employee Data
- mAbxience has 1208 Employees.
- mAbxience grew their employee count by 11% last year.
mAbxience's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Chief Development Officer - Member the Executive Committee, mAbxience | Reveal Email/Phone |
4 | Head Analytical development | Reveal Email/Phone |
5 | Head Regulatory Operations | Reveal Email/Phone |
6 | Controller technician | Reveal Email/Phone |
7 | Global Quality Director | Reveal Email/Phone |
8 | Global Commercial Director | Reveal Email/Phone |
9 | Associate Director Regulatory Affairs CMC | Reveal Email/Phone |
10 | Director médico | Reveal Email/Phone |
mAbxience Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $9.6M | 62 | 9% | N/A | N/A |
#2 | $14.4M | 93 | 4% | N/A | N/A |
#3 | $93M | 600 | 16% | N/A | N/A |
#4 | $37.7M | 243 | 42% | N/A | N/A |
#5 | $66.5M | 429 | 31% | N/A | N/A |
#6 | $9.1M | 59 | -12% | N/A | N/A |
#7 | $41.5M | 268 | -3% | N/A | N/A |
#8 | $40.1M | 259 | -25% | N/A | N/A |
#9 | $11.3M | 73 | 20% | N/A | N/A |
#10 | $187.2M | 1208 | 11% | N/A | N/A |
What Is mAbxience?
mAbxience is a high growth international biotechnology company specialized in the research, development, manufacture and global commercialization of biopharmaceutical products to treat and prevent diseases across different therapeutic areas.
keywords:N/AN/A
Total Funding
1208
Number of Employees
$187.2M
Revenue (est)
11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $174.3M | 1245 | 21% | N/A |
#2 | $366.9M | 1248 | -16% | N/A |
#3 | $175.7M | 1255 | 11% | N/A |
#4 | $176.4M | 1260 | 19% | N/A |
#5 | $777.9M | 1303 | 26% | N/A |